State Institution "Republican Scientific and Practical Center "Cardiology"
Minsk, Belarus
Location status: Recruiting
Location contact
Henadzi Popel
CONTACT
Ivan Maiseyenka
CONTACT
NCT Number: NCT05800821
Cerebral hyperperfusion syndrome (CHS) was initially described as a clinical complication following carotid endarterectomy (CEA), but it may occur after both CEA and carotid artery stenting. It is characterised by throbbing ipsilateral frontotemporal or periorbital headache, and sometimes diffuse headache, eye and facial pain, vomiting, confusion, macular oedema, visual disturbances, focal motor seizures with frequent secondary generalisation, focal neurological deficits, and intracerebral or subarachnoid haemorrhage.
Knowledge of CHS among physicians remains limited. Most studies report an incidence of 1-3% after carotid endarterectomy. CHS is most common in patients with increases of more than 100% in cerebral perfusion compared with baseline after carotid revascularization, and is rare in patients with perfusion increases of less than 100% compared with baseline.
The pathophysiological mechanism of CHS is only partially understood. The chronic low-flow state induced by severe carotid disease results in compensatory dilation of cerebral vessels distal to the stenosis, as part of the normal autoregulatory response to maintain adequate cerebral blood flow (CBF). In this chronically dilated state, the vessels lose their ability to autoregulate vascular resistance in response to changes in blood pressure. Dysautoregulation has been shown to be proportional to the duration and severity of chronic hypoperfusion. After revascularization and reperfusion, impaired cerebral autoregulation may contribute to a cascade of intracranial microcirculatory changes, with an inability to respond adequately to the augmentation of CBF following carotid recanalization.
Although most patients present with mild symptoms and signs, progression to severe and life-threatening complications can occur if CHS is not recognised and treated promptly. Because CHS is diagnosed on the basis of several non-specific signs and symptoms, patients may be misdiagnosed as having one of the better-known causes of perioperative complications, such as thromboembolism.
Interested in participating?
Request Info30 year–80 year
All sexes
Observational
Minsk, Belarus
Location status: Recruiting
Henadzi Popel
CONTACT
Ivan Maiseyenka
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Carotid revascularization
Time frame: Occurrence of symptoms within 30 postoperative days
The diagnosis of cerebral hyperperfusion syndrome will be based on the following criteria:
Contact information is provided by the study sponsor or research team.
Henadzi Popel
CONTACT
Ivan Maiseyenka
CONTACT
State Institution "Republican Scientific and Practical Center" Cardiology, Belarus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04470687
Arterial Occlusive Diseases, Atheroma; Carotid Artery
Paris, France
View Trial DetailsNCT05134493
Arterial Occlusive Diseases, Brain Diseases
Modena, Italy
View Trial DetailsNCT02629653
Arterial Occlusive Diseases, Body Temperature Changes
Rome, Italy
View Trial DetailsNCT06924593
Arterial Occlusive Diseases, Brain Diseases
Beijing, China
View Trial Details